



**FTSE  
RUSSELL**  
An LSEG Business

## Celltrion Inc (Korea): Stock Acquisition of Celltrion Healthcare (Korea) Changes in FTSE RAFI™ Index Series

08 December 2023

Subject to the completion of the Stock Acquisition of Celltrion Healthcare (Korea, constituent) by Celltrion Inc (Korea, constituent), please see details of affected indexes and effective dates below:

Index	Effective From Start of Trading
FTSE RAFI All World 3000 Index	18 December 2023
FTSE RAFI All World 3000 Index - QSR	18 December 2023
FTSE RAFI Developed ex US Mid Small 1500 Index	18 December 2023
FTSE RAFI Developed Mid Small ex US 1500 Index - QSR	18 December 2023

Please note:

1. Celltrion Healthcare is expected to be suspended from trading from 18 December 2023.
2. The shares in issue of Celltrion Inc is based on the stock swap terms of 0.449262 Celltrion Inc shares for every Celltrion Healthcare share held.
3. The weight adjustment factor (WAF) of Celltrion Inc effective 18 December 2023 is based on the original proposing WAFs for both Celltrion Inc and Celltrion Healthcare as per December 2023 quarterly review and further calculated based on the stock swap terms.
4. The weight adjustment factor (WAF) of Celltrion Inc effective 18 December 2023 is based on the original proposing WAF for Celltrion Inc as per December 2023 quarterly review and further adjusted due to the index share change resulting from the stock acquisition of Celltrion Healthcare (non constituent of FTSE RAFI All World 3000 Index - QSR).

For further information please contact FTSE Russell Client Services at [info@ftserussell.com](mailto:info@ftserussell.com) or call:

Australia	+61 (0) 2 7228 5659
Hong Kong	+852 2164 3333
Japan	+81 3 6441 1430
London	+44 (0) 20 7866 1810
New York	+1877 503 6437

Alternatively please visit our website at [lseg.com/ftse-russell](https://lseg.com/ftse-russell)

